MTOR and gastric adenocarcinoma: There are many novel compounds available today targeting different molecular pathways of gastric cancer such as HER2, EGFR, MET, FGFR, and PI3K/MTOR, which could potentially be used for the treatment of gastric adenocarcinomas.